Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Type 1 lissencephaly due to doublecortin (DCX) gene mutations is a semi-dominant X-linked disease characterized by intellectual deficiency and seizures that are more severe in male patients.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 5 | Seizure, Dysarthria, Ataxia |
Muscles | 1 | Axial hypotonia |
Eyes | 1 | Nystagmus |
Growth and development | 1 | Postnatal growth retardation |
DCX pathogenic variants cause an X-linked neuronal migration disorder neuroradiologically comprising an anterior predominant "agyria-pachygyria-band" spectrum of cortical malformations. This includes lissencephaly, referring to a "smooth brain" with a thick cortex and absent (agyria) and/or abnormally wide gyri (pachygyria) in hemizygous males with or without subcortical band heterotopia (SBH). Heterozygous females or rare males with mosaic or "mild" pathogenic variants present with diffuse thick or thin or anterior-predominant SBH, which may be accompanied by frontoparietal pachygyria . To date, more than 300 individuals have been identified with a pathogenic variant in DCX . The following description of the phenotypic features associated with this condition is based on these reports. Table 2. Select Features of DCX-Related Disorders
Feature1 | Males2(n=76) | Heterozygous Females3 |
|---|---|---|
Ascertained Through Familial Testing4(n=92) | Ascertained Through Diagnostic Workup of Clinical Features5(n=62) Asymptomatic | 0% |
Abnormal brain imaging (i.e., cortical malformations incl classic lissencephaly) | 100% | 85% |
Neonatal normal | 33/33 | — |
Moderate-to-severe motor impairment | 18/33 | — |
Non-ambulatory | 13/33 | — |
Walking w/support | 5/33 | — |
Walking independently w/o support | 15/33 | — |
Significant speech language impairment | 15/33 | — |
Moderate-to-severe intellectual disability | 100% | — |
100% Moderate-to-severe behavioral disturbances (incl autistic features, sleep disorder, /or agitation) | 10/33 | — |
60% Truncal hypotonia or spasticity | 7/11 | — |
29% Postnatal microcephaly (OFC 2 SDs below the mean) | 30% | — |
16% Seizures | 83% | — |
85% Intractable seizures | 49% | 78% NA = not applicable; OFC = orbitofrontal cortex; SD = standard deviation 1. , Median age at examination was 7.5 years for 33 individuals reported by Leger et al 2008 (range: 1.5-37 years); age range for 43 individuals reported by was 0.8-37 years. |
Source: GeneReviews — "DCX-Related Disorders"
DCX encodes doublecortin (365 aa). Microtubule-associated protein required for initial steps of neuronal dispersion and cortex lamination during cerebral cortex development. Highest expression in Brain Frontal Cortex BA9 (2.7 TPM) and Brain Hypothalamus (2.2 TPM).
Lissencephaly type 1 due to doublecortin gene mutation is associated with mutations in the DCX gene on chromosome X.
The DCX protein participates in DCXR tetramer reduces L-xylulose to xylitol, Defective DCXR does not reduce L-xylulose to xylitol, and MDM2 gene expression is repressed by NPAS4 pathways.
DCX is classified as a druggable target (Kinase category) with score 2.1.
About one third of all DCX pathogenic variants are recurrent, resulting in similar pathogenic variant-specific cortical phenotypes in and between families . A slight effect of the type and location of the DCX pathogenic variant on the resulting severity of the brain malformation for both SBH and classic lissencephaly has been suggested .
Source: GeneReviews — "DCX-Related Disorders"
Males. No instances of asymptomatic males with germline hemizygous DCX pathogenic variants have been reported, thus suggesting full penetrance of germline DCX pathogenic variants in males. However, males with postzygotic mosaic pathogenic variants may have milder clinical manifestations or, in rare cases, be asymptomatic. Mild clinical manifestations in the presence of hemizygous DCX pathogenic variants in the mosaic state have been anecdotally reported. As an example, a nine-year-old boy with thin subcortical band heterotopia and low hemizygosity (with a variant allele fraction of 13.6% for a p.Arg186His DCX pathogenic variant) developed focal seizures with motor onset primarily triggered by exercise at age 13 years .
Source: GeneReviews — "DCX-Related Disorders"
For the purposes of this GeneReview, the terms "male" and "female" are narrowly defined as the individual's biological sex at birth as it determines clinical care . DCX-related disorders are X-linked disorders involving abnormal neuronal migration observed by brain imaging; they include the following:
Classic thick lissencephaly, primarily in males
Subcortical band heterotopia (SBH), primarily in females
DCX-related disorders should be considered in probands with the following characteristic brain neuroimaging findings, in combination with early-onset epilepsy, developmental delay, and/or behavioral problems. A family history consistent with X-linked inheritance is an additional supportive finding.
Classic lissencephaly, usually in males
Source: GeneReviews — "DCX-Related Disorders"
Genes of interest in the differential diagnosis of DCX-related disorders are listed in . Table 3. Genes of Interest in the Differential Diagnosis of DCX-Related Disorders
Gene | Lissencephaly Gradient1 | Other Features/ Comment |
|---|---|---|
Diffuse lissencephaly | Posterior-predominant gradient (pa)2 | Anterior-predominant gradient (ap) |
CDK5 | + | Agyria, agenesis of corpus callosum, severe cerebellar pontine hypoplasia, dilated subarachnoid spaces; Dysmorphic facial features, lymphedema, arthrogryposis multiplex; Early lethality4 CRADD |
Genetic testing for DCX is available. Testing is considered confirmatory for diagnosis.
No approved treatments are currently available for lissencephaly type 1 due to doublecortin gene mutation. The disease remains an area of unmet medical need.
No clinical practice guidelines for DCX-related disorders have been published. In the absence of published guidelines, the following recommendations are based on the authors' personal experience managing individuals with this disorder. Note: The clinical spectrum observed in individuals with DCX pathogenic variants is extremely broad, from rare, very severely affected males with limited life expectancy to healthy females with a heterozygous or mosaic pathogenic DCX variant who may never develop any clinical features of a DCX-related disorder. Therefore, the information provided in the management section aims to address any clinical issues that may arise, and hence the more severely affected individuals within this clinical spectrum.
To establish the extent of disease and needs in an individual diagnosed with a DCX-related disorder, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended.
Table 4.
DCX-Related Disorders: Recommended Evaluations Following Initial Diagnosis
System/Concern | Evaluation | Comment
| Neurologic eval | • At initial diagnosis at least annually thereafter, esp for mgmt of epilepsy that should include an epilepsy specialist
Prolonged video EEGs may be required to fully characterize epilepsy burden or spells of unclear clinical etiology
To incl early brain imaging to characterize assess brain malformation
| Measurements of OFC, length/height, ...
Source: GeneReviews — "DCX-Related Disorders"
To date avoidance of any medications or other agents has not been suggested for individuals with DCX pathogenic variants. However, for all individuals with seizure disorders, trigger situations should be explored and avoided as much as possible.
Source: GeneReviews — "DCX-Related Disorders"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "DCX-Related Disorders"
View trials for lissencephaly type 1 due to doublecortin gene mutation
To monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations, the evaluations summarized in are recommended. Table 6. DCX-Related Disorders: Recommended Surveillance
System/Concern | Evaluation | Frequency |
|---|---|---|
Ophthalmologic involvement | Eval of refraction visual acuity | Per treating ophthalmologist(s) Low vision services |
Respiratory | Monitor for evidence of aspiration, respiratory insufficiency. | At each visit |
Transition to Adult Care | Develop realistic plans for adult life (see American Epilepsy Society Transitions from Pediatric Epilepsy to Adult Epilepsy Care). | Starting by age ~10 yrs ADHD = attention-deficit/hyperactivity disorder; ASD = autism spectrum disorder; ASM = anti-seizure medication; OT = occupational therapy; PT = physical therapy |
Source: GeneReviews — "DCX-Related Disorders"
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for lissencephaly type 1 due to doublecortin gene mutation.
15 publications have been identified in PubMed for lissencephaly type 1 due to doublecortin gene mutation. Research spans Basic Science / Preclinical (40%), Case Report / Case Series (33%), and Review / Meta-Analysis (13%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 6 | 40% |
Patient case studies | 5 | 33% |
Research summaries | 2 | 13% |
Disease patterns and progression | 2 | 13% |
Achkasova KA (2026). [PMID: 41892327](https://pubmed.ncbi.nlm.nih.gov/41892327/). *Cells*. [Review / Meta-Analysis]
Kim SY (2025). [PMID: 39513527](https://pubmed.ncbi.nlm.nih.gov/39513527/). *American journal of medical genetics. Part A*. [Epidemiology / Natural History]
Gamber A (2025). [PMID: 41004695](https://pubmed.ncbi.nlm.nih.gov/41004695/). *Neurology*. [Basic Science / Preclinical]
Jing XY (2025). [PMID: 40011197](https://pubmed.ncbi.nlm.nih.gov/40011197/). *Prenatal diagnosis*. [Case Report / Case Series]
Cakar MM (2025). [PMID: 41134416](https://pubmed.ncbi.nlm.nih.gov/41134416/). *Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology*. [Epidemiology / Natural History]
Sébastien M (2025). [PMID: 39966472](https://pubmed.ncbi.nlm.nih.gov/39966472/). *Nature communications*. [Basic Science / Preclinical]
Peer S (2025). [PMID: 40192980](https://pubmed.ncbi.nlm.nih.gov/40192980/). *Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology*. [Case Report / Case Series]
Mahendran G (2025). [PMID: 40806509](https://pubmed.ncbi.nlm.nih.gov/40806509/). *International journal of molecular sciences*. [Basic Science / Preclinical]
Zhang C (2025). [PMID: 39743596](https://pubmed.ncbi.nlm.nih.gov/39743596/). *Nature*. [Basic Science / Preclinical]
Kraus JEM (2024). [PMID: 38909268](https://pubmed.ncbi.nlm.nih.gov/38909268/). *Neural development*. [Case Report / Case Series]
Data assembled from 7 of 12 sources · Last updated Sep 19, 2026, 11:57 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
+ |
Other brain malformations typically seen include polymicrogyria, nodular heterotopia, thin corpus callosum, cerebellar basal ganglia abnormalities; Axonal neuropathy seen in some persons KIF2A |
+ | + | Severe IUGR; Arthrogryposis; Microcephaly6 |
NDE1 | + | Microcephaly; Simplified cortical gyral pattern; Thin or absent corpus callosum; Microhydranencephaly can be seen PAFAH1B1 |
RNU4ATAC | + | Assoc w/several phenotypes incl microcephalic osteodysplastic primordial dwarfism type I/III, Roifman syndrome, Lowry-Wood syndrome; Brain imaging abnormalities include pachygyria, heterotopia, agenesis of corpus callosum, cerebellar vermis hypoplasia |
TUBA1A | + | + |
Source: GeneReviews — "DCX-Related Disorders"